ArticleJournal of acquired immune deficiency syndromes (1999)2018
Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study.
Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Degree of Polypharmacy and Cognitive Function in Older Women with HIV.AIDS research and human retroviruses · 2022Article
- Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV.AIDS (London, England) · 2021Article
- Dietary intake is associated with neuropsychological impairment in women with HIV.The American journal of clinical nutrition · 2021Article
- Patterns and Predictors of Cognitive Function Among Virally Suppressed Women With HIV.Frontiers in neurology · 2021Article
- Neurocognitive Complications of HIV Infection in Women: Insights from the WIHS Cohort.Current topics in behavioral neurosciences · 2021Review
- Lifetime antiretroviral exposure and neurocognitive impairment in HIV.Journal of neurovirology · 2020Article
- Impaired Cognition Predicts Falls Among Women With and Without HIV Infection.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.Journal of neurovirology · 2019Observational
- HIV, Depression, and Cognitive Impairment in the Era of Effective Antiretroviral Therapy.Current HIV/AIDS reports · 2019Review
- Article
- Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women.Journal of acquired immune deficiency syndromes (1999) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 1 country.
Funding
Abstract
backgroundNeurocognitive impairment is a frequent and often disabling comorbidity of HIV infection. In addition to antiretroviral therapies, individuals with HIV infection may commonly use nonantiretroviral medications that are known to cause neurocognitive adverse effects (NC-AE). The contribution of NC-AE to neurocognitive impairment is rarely considered in the context of HIV and could explain part of the variability in neurocognitive performance among individuals with HIV.
settingWomen's Interagency HIV Study, a prospective, multisite, observational study of US women with and without HIV.
methodsAfter a literature review, 79 medications (excluding statins) with NC-AE were identified and reported by Women's Interagency HIV Study participants. We examined factors associated with self-reported use of these medications over a 10-year period. Generalized estimating equations for binary outcomes were used to assess sociodemographic, behavioral, and clinical characteristics associated with NC-AE medication use.
resultsThree thousand three hundred women (71% with HIV) and data from ∼42,000 visits were studied. HIV infection was associated with NC-AE medication use (odds ratio = 1.52; 95% confidence interval: 1.35 to 1.71). After adjustment for HIV infection status, other predictors of NC-AE medication use included having health insurance, elevated depressive symptoms, prior clinical AIDS, noninjection recreational drug use, and an annual household income of <$12,000 (Ps < 0.004). NC-AE medication use was less likely among women who drank 1-7 or 8-12 alcoholic drinks/week (vs. abstaining) (P < 0.04).
conclusionsHIV infection was associated with NC-AE medication use, which may influence determinations of HIV-associated neurocognitive impairment. Providers should consider the impact of NC-AE medications when evaluating patients with HIV and concurrent neurocognitive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.